Illumina, Inc. (NASDAQ:ILMN) Stake Boosted by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,688 shares of the life sciences company’s stock after purchasing an additional 374 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Illumina were worth $644,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Trivant Custom Portfolio Group LLC grew its holdings in Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after buying an additional 125 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in Illumina in the 4th quarter worth approximately $37,000. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares in the last quarter. Gradient Investments LLC grew its holdings in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC bought a new position in Illumina in the 4th quarter worth approximately $42,000. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 0.1 %

NASDAQ:ILMN traded up $0.10 during trading hours on Wednesday, hitting $122.60. 1,439,600 shares of the stock traded hands, compared to its average volume of 2,114,598. The firm has a 50 day moving average price of $110.74 and a 200 day moving average price of $123.82. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $195.64. The firm has a market cap of $19.53 billion, a price-to-earnings ratio of -15.04 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the business earned $0.08 EPS. The company’s revenue was down 1.0% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Scotiabank decreased their price objective on Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a report on Monday, May 6th. Robert W. Baird upped their target price on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Evercore ISI cut their target price on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research report on Tuesday, June 11th. Barclays upped their target price on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Finally, StockNews.com initiated coverage on Illumina in a research report on Sunday, June 30th. They issued a “buy” rating for the company. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $158.57.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.